Korro Bio (KRRO) Competitors $12.71 -0.88 (-6.48%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$13.12 +0.41 (+3.23%) As of 07/11/2025 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KRRO vs. PRME, VALN, BCAX, PGEN, SIGA, ATYR, ORKA, CAPR, CGEM, and MREOShould you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Prime Medicine (PRME), Valneva (VALN), Bicara Therapeutics (BCAX), Precigen (PGEN), Siga Technologies (SIGA), aTyr Pharma (ATYR), Oruka Therapeutics (ORKA), Capricor Therapeutics (CAPR), Cullinan Therapeutics (CGEM), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Korro Bio vs. Its Competitors Prime Medicine Valneva Bicara Therapeutics Precigen Siga Technologies aTyr Pharma Oruka Therapeutics Capricor Therapeutics Cullinan Therapeutics Mereo BioPharma Group Korro Bio (NASDAQ:KRRO) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Does the media refer more to KRRO or PRME? In the previous week, Prime Medicine had 7 more articles in the media than Korro Bio. MarketBeat recorded 9 mentions for Prime Medicine and 2 mentions for Korro Bio. Prime Medicine's average media sentiment score of 1.02 beat Korro Bio's score of 0.94 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, KRRO or PRME? Korro Bio has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Is KRRO or PRME more profitable? Korro Bio's return on equity of -51.64% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Korro BioN/A -51.64% -37.94% Prime Medicine N/A -107.87%-74.97% Do analysts prefer KRRO or PRME? Korro Bio currently has a consensus price target of $102.43, suggesting a potential upside of 705.89%. Prime Medicine has a consensus price target of $10.08, suggesting a potential upside of 131.80%. Given Korro Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Korro Bio is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has preferable earnings and valuation, KRRO or PRME? Korro Bio has higher earnings, but lower revenue than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKorro Bio$2.27M52.58-$83.58M-$9.44-1.35Prime Medicine$3.85M152.12-$198.13M-$1.61-2.70 Do insiders & institutionals have more ownership in KRRO or PRME? 13.2% of Korro Bio shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 4.6% of Korro Bio shares are held by company insiders. Comparatively, 22.9% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryKorro Bio beats Prime Medicine on 9 of the 16 factors compared between the two stocks. Get Korro Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRRO vs. The Competition Export to ExcelMetricKorro BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$127.62M$2.74B$5.62B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio-1.359.4228.0520.27Price / Sales52.58714.12429.5999.27Price / CashN/A165.3637.4658.16Price / Book0.744.608.055.49Net Income-$83.58M$31.26M$3.18B$250.45M7 Day Performance-1.47%4.80%3.60%4.77%1 Month Performance-9.08%5.42%4.03%7.66%1 Year Performance-74.14%-4.36%29.49%16.39% Korro Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRROKorro Bio1.5358 of 5 stars$12.71-6.5%$102.43+705.9%-72.3%$127.62M$2.27M-1.3570PRMEPrime Medicine3.9289 of 5 stars$3.80+22.2%$10.08+165.4%-27.5%$498.92M$3.85M-1.85234Positive NewsHigh Trading VolumeVALNValneva1.8404 of 5 stars$5.75-1.0%$15.50+169.6%-18.3%$494.40M$183.52M-4.83700News CoverageGap DownBCAXBicara Therapeutics2.1461 of 5 stars$9.01-0.2%$31.86+253.6%N/A$492.46MN/A0.0032PGENPrecigen4.1229 of 5 stars$1.59-1.9%$6.00+277.4%+11.6%$478.19M$3.92M-2.84190Analyst UpgradeSIGASiga Technologies2.2414 of 5 stars$6.73+0.6%N/A-22.1%$477.94M$138.72M10.0440News CoverageOptions VolumeATYRaTyr Pharma2.1014 of 5 stars$5.30-0.2%$20.20+281.1%N/A$472.61M$230K-6.5453Gap UpHigh Trading VolumeORKAOruka Therapeutics2.901 of 5 stars$13.29+5.5%$40.38+203.8%N/A$471.75MN/A-2.95N/APositive NewsCAPRCapricor Therapeutics2.5393 of 5 stars$9.90-3.4%$32.22+225.5%+66.4%$468.19M$22.27M-6.97101Trending NewsAnalyst ForecastGap DownCGEMCullinan Therapeutics1.7348 of 5 stars$7.42-5.0%$30.00+304.3%-52.4%$460.90MN/A-2.5530News CoveragePositive NewsGap UpMREOMereo BioPharma Group1.5799 of 5 stars$2.92+1.7%$7.60+160.3%-58.6%$456.33M$10M-41.7140News CoverageAnalyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies Prime Medicine Alternatives Valneva Alternatives Bicara Therapeutics Alternatives Precigen Alternatives Siga Technologies Alternatives aTyr Pharma Alternatives Oruka Therapeutics Alternatives Capricor Therapeutics Alternatives Cullinan Therapeutics Alternatives Mereo BioPharma Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRRO) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
